Eli Lilly and Co
Change company Symbol lookup
Select an option...
LLY Eli Lilly and Co
INTC Intel Corp
DVN Devon Energy Corp
CCL Carnival Corp
OKE ONEOK Inc
BMY Bristol-Myers Squibb Co
KO Coca-Cola Co
DOW Dow Inc
CTVA Corteva Inc
COP Conocophillips
Go

Health Care : Pharmaceuticals | Large Cap Growth
Company profile

Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.

Closing Price
$365.25
Day's Change
3.53 (0.98%)
Bid
--
Ask
--
B/A Size
--
Day's High
365.83
Day's Low
361.55
Volume
(Light)
Volume:
1,039,094

10-day average volume:
3,176,973
1,039,094

EQUITY ALERT: Rosen Law Firm Encourages Barclays PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action - BCS

9:56 am ET September 27, 2022 (BusinessWire) Print

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Barclays PLC (NYSE: BCS) between February 18, 2021 and March 25, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than November 22, 2022.

SO WHAT: If you purchased Barclays securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Barclays class action, go to https://rosenlegal.com/submit-form/?case_id=8877 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 22, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements or omitted material information: (1) in Barclays reported financial statements (which have been restated); (2) by stating that Barclays internal controls over financial reporting were effective (which Barclays has admitted were not effective and had a material weakness); and (3) by failing to disclose the over-issuance, and that Barclays Bank PLC ("BBPLC"), a wholly owned subsidiary of Barclays, was violating U.S. securities laws and/or SEC regulations, subjecting Barclays to legal liability. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Barclays class action, go to https://rosenlegal.com/submit-form/?case_id=8877 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220927005838/en/

SOURCE: The Rosen Law Firm, P.A.

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com 
pkim@rosenlegal.com 
cases@rosenlegal.com 
www.rosenlegal.com
comtex tracking

COMTEX_415394170/1006/2022-09-27T09:56:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.